Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microglial Activation Role In ALS (MARIA)
NCT02405403Phase 1Withdrawn
- Sponsor
- University Hospital Tours
- Start
- Mar 2015
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DPA-714 in amyotrophic lateral sclerosis (ALS), sponsored by University Hospital Tours. Primary endpoint: Concentration of cytokines in cerebrospinal fluid at 18 months. Planned start Mar 2015; status: withdrawn.
02
Drugs
DPA-714
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02405403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02405403.